Advances in resistance mechanisms and counterstrategies for antibody‑drug conjugates in HER2‑low and HER2‑ultralow breast cancer (Review)
Oncology Reports · 20.10.2026 · 56 (6) · 1-15
DOI: 10.3892/or.2026.9214 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reports, online erschienen am 20.10.2026. Verfasst von Xiaojie Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Faculty of Medicine, Yangzhou University, Yangzhou, Jiangsu 225000, P.R. China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Immunoconjugates. Die Arbeit nennt 104 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medical College, Faculty of Medicine, Yangzhou University, Yangzhou, Jiangsu 225000, P.R. China.
- School of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, Hebei 050000, P.R. China.
- Department of Thyroid and Breast Surgery, Changxing Hospital of Traditional Chinese Medicine, Huzhou, Zhejiang 313000, P.R. China.
Zitieren
APA
Yu, X., Ren, M., & Yao, L. (2026). Advances in resistance mechanisms and counterstrategies for antibody‑drug conjugates in HER2‑low and HER2‑ultralow breast cancer (Review). Oncology Reports, 56(6), 1-15. https://doi.org/10.3892/or.2026.9214
Vancouver
Yu X, Ren M, Yao L. Advances in resistance mechanisms and counterstrategies for antibody‑drug conjugates in HER2‑low and HER2‑ultralow breast cancer (Review). Oncology Reports. 2026;56(6):1-15. doi:10.3892/or.2026.9214
BibTeX
@article{Yu2026,
author = {Yu, Xiaojie and Ren, Meilin and Yao, Longdi},
title = {Advances in resistance mechanisms and counterstrategies for antibody‑drug conjugates in HER2‑low and HER2‑ultralow breast cancer (Review)},
journal = {Oncology Reports},
year = {2026},
volume = {56},
number = {6},
pages = {1--15},
doi = {10.3892/or.2026.9214}
}
EUVIMED